L'intérêt à découvert pour GSK donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de GSK. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

GSK (NYSE:GSK) Stock, Rapport sur les intérêts à découvert

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GlaxoSmithKline

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK PLC

Goldseek Resources Inc Ordinary Shares

GSK ORD

President-elect Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. Trading in pharmaceutical stocks is shaky this week and the details are few surrounding a <a href="https://www.benzinga.com/general/politics">possible appointment</a>.
What To Know: Trump <a href="https://www.benzinga.com/news/24/10/41565423/trump-says-robert-kennedy-jr-can-run-wild-on-health-and-food-im-going-to-let-him-go-wild-on-the-medi">recently said</a> he would let Kennedy &#8220;go wild on health&#8221; and could "do pretty much what he wants" in his administration, but the details remain murky.&nbsp;
Kennedy has a record of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies, <a href="https://www.nytimes.com/2024/11/06/us/politics/robert-kennedy-jr-donald-trump-health-care.html">according</a> to The New York Times. Thirteen measles outbreaks have occurred in the U.S. so far in 2024 versus four last year, and the trend coincides with lower measles vaccination rates, The Times report said, citing the CDC. Kennedy is outspoken about certain food ingredients and the state of key public health agencies including the Centers for Disease Control and Prevention, the Food and Drug Administration and the National Institutes of Health. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Kennedy said in <a href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">an interview </a>Wednesday with NBC News that Trump has not yet decided what his job in the new administration will be, but he did mention the prospect of being a &#8220;White House health czar.&#8221;
Kennedy said he wouldn&#8217;t "take away anybody&#8217;s vaccines," but the uncertainty surrounding his potential impact on the country's health care regulators caused vaccine-related stocks to drop. Investors may be trying to get ahead of any negative consequences related to a potential Kennedy appointment.  
&#8220;We view the Trump win as mixed for large-cap biopharma since it creates potential uncertainty regarding Food and Drug Administration independence,&#8221; said Leerink Partners analyst David Risinger, according to Investor's Business Daily.  
Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) ending the day down 2.78%, Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 3.9%, BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) down 3.9% and GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) closing down by 3.03%. 
Moderna reported its <a href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024">third-quarter results</a> Thursday morning with $1.8 billion in Spikevax sales and was trading down in the late afternoon. Shares of the other vaccine makers are recovering Thursday, but the uncertainty <a href="https://www.benzinga.com/news/24/11/41704387/robert-kennedy-jr-says-he-will-advise-all-us-water-systems-to-remove-fluoride-on-day-1-of-trump-admi">may continue</a> as details emerge on a Kennedy role in the forthcoming Trump administration. 
"Shoot first reaction being felt across the vaccine complex," wrote Mizuho analyst Jared Holz, as <a href="https://www.wsj.com/livecoverage/stock-market-today-fed-meeting-dow-nasdaq-sp500-live-11-06-2024/card/vaccine-stocks-drop-on-worries-about-an-rfk-jr-role-dBPxZf8JJnNqL1Zi5yZY">reported </a>by the Wall Street Journal. He added that "for now, state mandates for many treatments remain intact."
MRNA, PFE, BNTX, GSK Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Moderna shares are up 2.67% at $50.42, Pfizer shares are up 0.35% at $27.44, BioNTech shares are up 1.29% at $108.02 and GSK shares are up 1.77% at $36.54 ahead of the close Thursday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Image: Shutterstock

Biotech

Government

News

Health Care

Politics

Movers

General

BNTX

MRNA

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'

<ul>
<li>New analyses highlight use of long-acting injectable Vocabria + Rekambys (cabotegravir + rilpivirine LA) in clinical trial and real-world populations, and the economic and public health impact of Apretude (cabotegravir LA for PrEP)</li>
<li>Findings from the DOLCE study explore the efficacy of 2-drug regimen Dovato (dolutegravir/lamivudine) compared to three-drug regimen in people with advanced HIV with CD4 count ≤ 200 cells/mm³</li>
<li>Additional key abstracts include findings from pipeline bNAb asset, VH3810109, as a potential approach to treating HIV</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio and pipeline at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 – 13 November 2024. Spanning 42 abstracts, the data showcases long-acting and two-drug regimens as care options for diverse populations in the face of a continuing HIV epidemic.

GSK, Pfizer And Shionogi's ViiV Healthcare Expands On Real-World Data Supporting Use Of Long-Acting Therapies In Diverse Patient Populations At HIV Glasgow

GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49

Guggenheim analyst Seamus Fernandez downgrades GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) from Buy to Neutral.

Downgrades

Analyst Ratings

Guggenheim Downgrades GSK to Neutral

<a href="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon" title="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon">https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon</a>

NVAX

USDA Says H5N1 Bird Flu Detected In Swine For The First Time In U.S. In Oregon Backyard Farm; There Is No Concern About Safety Of The Nation's Pork Supply As A Result Of This Finding On HPAI Detections In Oregon Backyard Farm

USDA To Begin Bulk Milk Testing For Bird Flu Nationwide Following Pressure From Industry And Veterinary Groups; New Effort Aims To Curb Rapid Spread Among Dairy Herds

Wednesday,&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimated sales of $10.78 billion</a>.
Vaccine sales fell 18% (-15% at constant currency) to 2.65 billion pounds.
Vaccine sales performance was primarily impacted by lower sales of Arexvy with changes in Advisory Committee on Immunization Practices (ACIP) guidelines, prioritization of COVID-19 vaccinations in the quarter, lower seasonal infections, and a tough comparator following launch stocking last year.
Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41529605/just-after-pfizers-rsv-vaccine-approval-for-younger-adults-gsk-layouts-encouraging-preliminary-da" rel="noreferrer noopener">Just After Pfizer&#8217;s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population</a>
Specialty Medicine sales increased 14% to 2.97 billion pounds. HIV drug revenues increased by 8% to&nbsp;1.75 billion pounds.
General Medicines sales rose by 3% to&nbsp;2.39 billion pounds. The company added General Medicines, including Trelegy, also continued to perform better than expected.
Trelegy (asthma drug) sales reached 600 million pounds, up 12%
The company reported core EPS of $1.29 (49.7 pence), up 5%&nbsp;on a&nbsp;constant currency and down 1% on a reported basis, beating the consensus of $1.23.
&#8220;Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, &#8221; said Emma Walmsley, CEO.
Guidance:&nbsp;GSK reaffirms 2024 adjusted EPS growth of 10%- 12%, with core operating profit increasing by 11%- 13% and sales expanding by 7% %- 9%.
Vaccine sales are expected to decrease in low-single-digit percent <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40073220/british-pharma-giant-gsks-blockbuster-shingles-and-respiratory-syncytial-virus-vaccine-q2-sales-m" rel="noreferrer noopener">compared to earlier guidance</a> of an increase in low to mid-single-digit percent.
Specialty Medicine revenue is expected to grow at a high teens percent, compared to a prior growth range of mid-to-high teens percent.
General Medicines 2024 sales are forecasted to increase at mid-single digit percent compared to earlier guidance of low to mid-single digit percent.
Price Action:&nbsp;At last check on Wednesday, GSK stock was down 4.69% to $36.38 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41608586/coya-therapeutics-high-dose-interleukin-2-misses-the-mark-in-mid-stage-alzheimers-study" target="_blank" rel="noreferrer noopener">Coya Therapeutics&#8217; High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer&#8217;s Study</a></li>
</ul>
Photo via Wikimedia Commons

Earnings

Large Cap

Guidance

Eurozone

Trading Ideas

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024

WIIM

GSK shares are trading lower after the company reported mixed Q3 financial results.

Guidance and outlooks, assumptions and cautionary statements 2024 Guidance&nbsp;
GSK confirms its full-year sales, core profit and EPS guidance at constant exchange rates (CER) and expects to deliver broadly around the middle of the existing ranges.&nbsp;
Turnover is expected to increase between 7 to 9 per cent. Core operating profit is expected to increase between 11 to 13 per cent and Core Earnings per share is expected to increase between 10 to 12 per cent.&nbsp;
The Group revises turnover expectations for Vaccines to a decrease of low-single digit per cent, for Specialty Medicines to an increase of high teens per cent and for General Medicines to an increase of mid-single digit per cent.&nbsp;
This guidance is provided at CER and excludes any contribution from COVID-19 related solutions

GSK Reaffirms Its 2024 Outlook, Sees Turnover Growth Of 7%-9%, With Core Operating Profit Growth Of 11%-13%, And Core EPS Growth Of 10%-12%

GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.23 by 4.88 percent. This is a 1.57 percent increase over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $10.418 billion which missed the analyst consensus estimate of $10.781 billion by 3.37 percent. This is a 1.49 percent increase over sales of $10.265 billion the same period last year.

Earnings Beats

Earnings Misses

GSK Q3 2024 Adj. EPS $1.29 Beats $1.23 Estimate, Sales $10.418B Miss $10.781B Estimate

<a href="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12" title="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12">https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12</a>.

Macro Notification

US CDC Reports 36 H5 Bird Flu Cases In U.S. Since April; Six Cases In Washington Poultry Workers Confirmed Last Week; No Person-To-Person Spread Detected; Public Risk Remains Low But Higher For Those Exposed To Infected Animals; 15 Cases Linked To Infected Poultry And 20 To Sick Dairy Cows

GSK Acquires CMG1A46 From Chimagen Biosciences For $300M To Boost Immunology Pipeline, Targeting B Cell-Driven Autoimmune Diseases Like Lupus; Chimagen Eligible For Additional $550M In Milestone Payments

GOOG

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Google To Launch New "Sexual Health & Wellness" Policy On November 11, Permitting Promotion Of Personal Lubricants And Prescription Drugs In Select Countries

IDE275 (GSK959) has demonstrated robust and selective synthetic lethality preclinically in the high microsatellite instability (MSI-High) biomarker setting, and the Phase 1 clinical trial will enroll patients having tumors characterized by MSI-High.
<div>IDEAYA to receive a&nbsp;$7 million&nbsp;payment for IND acceptance, and potential future aggregate milestones of up to&nbsp;$950 million. IDEAYA has a 50/50 US Profit Share and an 80/20 (GSK/IDEAYA) global research and development cost share</div>

IDYA

IDEAYA Biosciences Reveals Clearance Of Investigational New DrugApplication With FDA For Initiation Of Phase 1 Clinical Trial To Evaluate Werner Helicase Development Candidate IDE275

On Thursday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for lower <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41512646/new-data-for-arexvy-gsks-respiratory-syncytial-virus-vaccine-show-potential-to-help-protect-a-broa" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
The data show that the vaccine has the potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV.
In the U.S. alone, the number of adults aged 18-49 with at least one risk factor that could put them at risk for RSV disease could exceed 21 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41278571/gsk-pfizer-face-declining-respiratory-syncytial-virus-vaccine-sales-due-to-narrow-age-recommendat" rel="noreferrer noopener">GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations</a>
The vaccine is currently approved for active immunization to prevent RSV-LRTD in adults aged 60 and older and in adults aged 50-59 at increased risk.
There are currently no RSV vaccines recommended for adults younger than 60 years of age who are at increased risk for RSV disease.
In the phase 3b trial, a single dose of the vaccine elicited robust immune responses in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions (n=395).
The immune response was non-inferior to that observed in adults 60 and older (n=417), meeting the trial&#8217;s co-primary endpoints.
In the phase 2b trial, a single dose of the vaccine showed a robust immune response in adults aged 18 and older who are immunocompromised due to kidney or lung transplant (n=131), with a second dose (n=130) eliciting responses similar to those of healthy adults aged 50 and older who received one dose (n=125).
These immune responses were consistent for RSV-A and RSV-B subtypes in all groups (those who received 1 or 2 doses).
Earlier this week, the FDA approved Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), the company&#8217;s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">who are at high risk</a>.
In June, the U.S. Centers for Disease Control and Prevention&#8217;s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">aged 75 and above</a>.
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41278571/gsk-pfizer-face-declining-respiratory-syncytial-virus-vaccine-sales-due-to-narrow-age-recommendat" rel="noreferrer noopener">additional data became available</a>.
Price Action: GSK stock is down 0.53% at $37.78 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41526261/verizon-faces-slower-growth-declining-cash-flow-in-2025-analyst-downgrades-stock" target="_blank" rel="noreferrer noopener">Verizon Faces Slower Growth, Declining Cash Flow In 2025, Analyst Downgrades Stock</a></li>
</ul>

Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population

<a href="https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers" title="https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers">https://www.cdc.gov/bird-flu/spotlights/missouri-h5n1-serology-testing.html#:~:text=Conclusion%20of%20Missouri%20Investigation%3A,of%20five%20health%20care%20workers</a>.

CDC Issues Report On Missouri H5N1 Serology Testing; Confirms No Human-To-Human Transmission Of H5 Bird Flu Detected In US

<ul>
<li>Single dose of vaccine-elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.</li>
<li>Two doses of vaccine in immunocompromised adults aged 18 and older elicited immune responses similar to one dose in healthy adults aged 50+ and with an acceptable safety profile.</li>
<li>In the US alone, adults aged 18-49 with at least one risk factor for RSV disease could exceed 21 million.</li>
</ul>

GSK Announced New Preliminary Data For Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) In Adults Aged 18-49 At Increased Risk For Lower Respiratory Tract Disease., Showing The Vaccine's Potential To Help Protect A Broader Group Of Adults

On Tuesday, the FDA approved Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo&nbsp; (Respiratory Syncytial Virus Vaccine), the company&#8217;s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41467625/u-s-fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-diseas" rel="noreferrer noopener">who are at high risk</a>.
Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older.
Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39672069/pfizers-rsv-vaccine-abrysvo-clears-concerns-over-preterm-birth-risk-safety-for-pregnant-women-new" rel="noreferrer noopener">up to 6 months of age</a>.
The FDA&#8217;s decision is based on inferred efficacy&nbsp;from the pivotal Phase 3&nbsp;MONeT&nbsp;study, which investigated the safety, tolerability, and immunogenicity of Abrysvo in adults at risk of RSV-associated disease due to certain chronic medical conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40311791/pfizers-respiratory-syncytial-virus-vaccine-data-shows-promise-in-subgroup-of-younger-immunocompr" rel="noreferrer noopener">Pfizer&#8217;s Respiratory Syncytial Virus Vaccine Data Shows Promise In Subgroup Of Younger Immunocompromised Patients</a>.
The company intends to submit MONeT results for publication in a peer-reviewed scientific journal and for presentation at an upcoming scientific conference.
In June, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">aged 75 and above</a>.
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41278571/gsk-pfizer-face-declining-respiratory-syncytial-virus-vaccine-sales-due-to-narrow-age-recommendat" rel="noreferrer noopener">additional data became available</a>.
U.S. sales of RSV vaccines from&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer have declined after regulators narrowed the age group eligible for the shots and determined they would be a one-time vaccination for now.
For Pfizer and GSK, RSV vaccines are critical as they seek to build new revenue streams before facing generic competition for their top-selling drugs.
In 2023, an average of 440,000 people per week received RSV vaccines from GSK and Pfizer in September, with 65% opting for GSK's Arexvy. However, this September, the weekly average fell to 157,000.
Price Action: PFE stock is down 0.36% at $28.74 at last check Wednesday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41487340/stride-rockets-on-q1-results-enrollments-up-18-5-eps-smashes-estimates" target="_blank" rel="noreferrer noopener">Stride Rockets On Q1 Results: Enrollments Up 18.5%, EPS Smashes Estimates</a>.</li>
</ul>

Equities

FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Dividend Yield: 6.36%</li>
<li>JP Morgan analyst Chris Schott downgraded the stock from Neutral to Underweight and raised the price target from $18 to $20 on Sept. 6. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29. This analyst has an accuracy rate of 68%</li>
<li>Recent News: Organon will release its third quarter financial results on Oct. 31.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">atest OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png" alt="" class="wp-image-604777" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21054143/image-181-768x717.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.15%</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26. This analyst has an accuracy rate of 64%.</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $22 to $19 on Aug. 21. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Premier will release financial results for its fiscal 2025 first quarter on Tuesday, Nov. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"> latest PINC news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png" alt="" class="wp-image-604724" style="width:700px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21050948/image-178-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.</li>
<li>Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 16, the FDA accepted GSK's marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with uncomplicated urinary tract infections (uUTIs).</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1">trend in GSK stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png" alt="" class="wp-image-604726" style="width:654px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21051023/image-179-768x711.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Dividends

Price Target

Pre-Market Outlook

Markets

PINC

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

GSK plc (LSE/NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) announced it is investing £50 million into a major new five-year collaboration with the University of Cambridge and Cambridge University Hospitals, to accelerate research and development into immune-related diseases. The collaboration, which will be called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), builds on GSK and Cambridge University's existing scientific relationship and will aim to find ways to more precisely treat immune-related disease with existing therapies, as well as develop new ones more rapidly. It will do this by enhancing our existing focus on understanding mechanisms of disease onset, disease progression, patient response to therapies and developing translational biomarkers.

GSK, Cambridge University Announced New Five-Year Collaboration In Kidney And Respiratory Disease

Deutsche Bank lowered the firm's price target on GSK (GSK) to 1,700 GBp from 1,850 GBp and keeps a Buy rating on the shares. Published first on The...

GSK price target lowered to 1,700 GBp from 1,850 GBp at Deutsche Bank

JPMorgan lowered the firm's price target on GSK (GSK) to 1,440 GBp from 1,550 GBp and keeps an Underweight rating on the shares. Published first on...

GSK price target lowered to 1,440 GBp from 1,550 GBp at JPMorgan

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price target of p1,5...

GlaxoSmithKline (GSK) Receives a Hold from Kepler Capital

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £...

Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to find out… 2024 has been a breakout year for Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), with its shares surging nearly 56% year-to-date. This growth is largely driven by the company's blockbuster drugs in the diabetes and obesity markets, particularly Mounjaro and Zepbound. In addition, the recent FDA approval of its eczema drug, EBGLYSS, in September has garnered significant attention.
But with these wins under its belt, does Eli Lilly remain a top healthcare stock? Let's find out.
Lilly's latest win
On September 25, LLY received FDA approval for its new eczema treatment, <a href="https://investor.lilly.com/news-releases/news-release-details/new-data-show-lillys-ebglysstm-lebrikizumab-lbkz-provided">Ebglyss</a>. Unlike traditional topical treatments like creams or ointments, Ebglyss is an injectable designed for patients (aged 12 and older) with moderate-to-severe eczema who don't find relief with topical medications. This medication is a monthly injection that can be used on its own or alongside topical corticosteroids.
According to the company, about 16.5 million adults in the U.S. suffer from eczema, with roughly 40% experiencing severe symptoms such as cracked and bleeding skin, itchiness, and rashes. It reported that more than 80% of patients who received Ebglyss for three years were able to manage their eczema effectively.
Weight-Loss Market Expansion
Beyond dermatology, LLY continues to expand its footprint in the weight-loss market. On August 20, LLY announced that its weight-loss drug, tirzepatide, reduced the risk of developing type 2 diabetes by 94% among patients with prediabetes and obesity while also helping them lose an average of nearly 23% of their body weight.
Further, to make this weight-loss drug more accessible, LLY introduced a lower-cost version of tirzepatide under the brand name Zepbound, offering single-dose vials priced at least 50% below similar treatments on the market. This strategy could further expand its market reach and drive additional revenue growth.
Strong Financials
LLY's total revenue for the fiscal <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue">second quarter</a> (ended June 30, 2024) increased 36% year-over-year to $11.30 billion, driven by the sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. Revenue from Lily's Verzenio also saw a substantial uptick, growing by 44% year-over-year to $1.33 billion.
Its non-GAAP gross margin also increased 40% from the year-ago value to $9.27 billion, while its operating income rose 74.7% from the prior-year quarter to $7.25 billion. Moreover, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and earnings per share amounted to $3.54 billion and $3.92, representing an increase of 85.9% and 85.8%, respectively.
Buoyed by this strong performance, the company increased its full-year 2024 revenue guidance by $3 billion and non-GAAP EPS forecast by $2.60 to the range of $16.10 to $16.60. LLY also plans to bolster its production of diabetes and weight-loss drugs later this year.
Rosy Annual Forecasts
The consensus revenue estimate for the current year ending December 31, 2024, stands at $46.21 billion, signaling a 35.4% year-over-year increase. Moreover, the company's EPS is anticipated to witness an impressive 111.6% uptick from the previous year, reaching $13.37.
Looking ahead, analysts anticipate a 25.7% increase in revenue for the fiscal year 2025, with projections reaching $58.08 billion. Similarly, EPS for the next year is expected to grow 71.8% from the prior year, settling at $22.98.
POWR Ratings Show Promise
LLY's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall B rating, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. LLY has a B grade for Growth, which is consistent with its strong financial performance in the last reported quarter.
LLY is ranked #42 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to access LLY's Value, Momentum, Stability, Sentiment, and Quality ratings.
Bottom Line
Beyond its success in weight management, the company is expanding its reach into areas like Alzheimer's, eczema, and even artificial intelligence. Moreover, the recent FDA approval of Ebglyss for eczema is yet another win, adding to LLY's growing portfolio of blockbuster drugs. With the global eczema market expected to <a href="https://www.globenewswire.com/en/news-release/2024/08/05/2924288/0/en/Global-Atopic-Dermatitis-Treatment-Market-to-expand-at-an-11-1-CAGR-from-2024-to-2034-totaling-USD-43-241-1-Million-Future-Market-Insights-Inc.html">more than double</a> by 2034, the company's new treatment has the potential to significantly boost revenue and keep the stock on its upward path.
Over the past year, the stock has gained 55.5% to close the last trading session at $909.15. Given this momentum, strong financials, and an optimistic outlook, we believe that adding LLY to your portfolio could be beneficial.
How Does Eli Lilly and Company (LLY) Stack Up Against Its Peers?
While LLY has an overall grade of B, equating to a Buy rating, you may also check out these other A-rated (Strong Buy) stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry: Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>), GSK plc (<a href="https://stocknews.com/stock/GSK/">GSK</a>) and AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>). To explore more medical pharmaceutical stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $896.45 per share on Wednesday afternoon, down $12.70 (-1.40%). Year-to-date, LLY has gained 54.53%, versus a 23.09% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lly-nvs-gsk-abbv-is-eli-lilly-still-a-top-healthcare-stock-after-its/>Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, consists of...

GlaxoSmithKline Updates Share Capital and Voting Rights

M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more

Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total vo...

GSK Pharma put volume heavy and directionally bearish

Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market

ABBV

ALTR

AMKBY

AVTE

GLYC

PARA

SIEGY

SMAWF

SRCL

STZHF

TRUE

TTWO

Press Releases

GSK and Flagship Pioneering partner to discover novel medicines and vaccines

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

AGEN

ALEC

ANVS

FHTX

MYGN

OMGA

PSNL

QGEN

SANA

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

GSK

Intérêt court

GSK (NYSE:GSK) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL